Literature DB >> 16735139

CD4+CD25+ Tregs and NKT cells: regulators regulating regulators.

Antonio La Cava1, Luc Van Kaer.   

Abstract

CD4+CD25+ regulatory T cells (Tregs) and natural killer T (NKT) cells are two populations of T lymphocytes that can independently regulate adaptive and innate immune responses. Although most studies have investigated the regulatory properties of these T-cell subsets independently of each other, recent reports have provided evidence for cross-talk between Tregs and NKT cells, and, consequently, the immunoregulatory networks are seen in a new perspective. Activated NKT cells seem to modulate quantitatively and qualitatively Treg function through IL-2-dependent mechanisms, whereas Tregs can suppress the proliferation, cytokine release and cytotoxic activity of NKT cells by cell-contact-dependent mechanisms. Importantly, Tregs and NKT cells share crucial signaling pathways that could be responsible for their concerted responses. The advances in our understanding of the interactions between distinct subsets of regulatory T cells in autoimmunity might unveil new methods for harnessing these cells with immunotherapeutic properties.

Entities:  

Mesh:

Year:  2006        PMID: 16735139     DOI: 10.1016/j.it.2006.05.003

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  80 in total

1.  Reduced frequency of NKT-like cells in patients with progressive chronic lymphocytic leukemia.

Authors:  Farhad Jadidi-Niaragh; Mahmood Jeddi-Tehrani; Bita Ansaripour; Seyed Mohsen Razavi; Ramazan Ali Sharifian; Fazel Shokri
Journal:  Med Oncol       Date:  2012-06-06       Impact factor: 3.064

Review 2.  CD8⁺ T Cell-Independent Immune-Mediated Mechanisms of Anti-Tumor Activity.

Authors:  G Elizabeth Pluhar; Christopher A Pennell; Michael R Olin
Journal:  Crit Rev Immunol       Date:  2015       Impact factor: 2.214

3.  Reduced levels of both circulating CD4+ CD25+ CD127(low/neg) and CD4+ CD8(neg) invariant natural killer regulatory T cells in stable heart transplant recipients.

Authors:  M Chen; M Mohtize; M-F Matteï; J-P Villemot; C Kohler; G C Faure; M C Béné; M de Carvalho Bittencourt
Journal:  Clin Exp Immunol       Date:  2010-10-29       Impact factor: 4.330

4.  On the definition of a criterion of immunogenicity.

Authors:  Thomas Pradeu; Edgardo D Carosella
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-13       Impact factor: 11.205

Review 5.  Cutaneous perspectives on adaptive immunity.

Authors:  Michael Girardi
Journal:  Clin Rev Allergy Immunol       Date:  2007-10       Impact factor: 8.667

6.  Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial.

Authors:  Mark A Exley; Phillip Friedlander; Nadia Alatrakchi; Lianne Vriend; Simon Yue; Tetsuro Sasada; Wanyong Zeng; Yo Mizukami; Justice Clark; David Nemer; Kenneth LeClair; Christine Canning; Heather Daley; Glenn Dranoff; Anita Giobbie-Hurder; F Stephen Hodi; Jerome Ritz; Steven P Balk
Journal:  Clin Cancer Res       Date:  2017-02-13       Impact factor: 12.531

7.  CD70 Inversely Regulates Regulatory T Cells and Invariant NKT Cells and Modulates Type 1 Diabetes in NOD Mice.

Authors:  Cheng Ye; Benjamin E Low; Michael V Wiles; Todd M Brusko; David V Serreze; John P Driver
Journal:  J Immunol       Date:  2020-08-31       Impact factor: 5.422

Review 8.  Regulatory NK-cell functions in inflammation and autoimmunity.

Authors:  Anna Lünemann; Jan D Lünemann; Christian Münz
Journal:  Mol Med       Date:  2009-05-11       Impact factor: 6.354

9.  Regulatory roles for NKT cell ligands in environmentally induced autoimmunity.

Authors:  Jaya Vas; Jochen Mattner; Stewart Richardson; Rachel Ndonye; John P Gaughan; Amy Howell; Marc Monestier
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

10.  Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against Leishmania.

Authors:  Blaise Dondji; Eszter Deak; Karen Goldsmith-Pestana; Eva Perez-Jimenez; Mariano Esteban; Sachiko Miyake; Takashi Yamamura; Diane McMahon-Pratt
Journal:  Eur J Immunol       Date:  2008-03       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.